Ladenburg raised the firm’s price target on Alpha Tau (DRTS) to $14 from $12 and keeps a Buy rating on the shares after the company announced interim results from the first three patients enrolled in its U.S. Alpha DaRT REGAIN trial. If results remain consistent, Alpha DaRT could move earlier in the treatment paradigm, including frontline use, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DRTS:
- Alpha Tau price target raised to $15 from $12 at H.C. Wainwright
- Alpha Tau Wiped Out Visible Tumors in Two of Three Brain Cancer Patients in Its First U.S. Trial
- Alpha Tau Medical Shares Interim U.S. Glioblastoma Trial Data for Alpha DaRT
- Alpha Tau announces interim data from REGAIN trial
- Alpha Tau Posts Strong Interim REGAIN Data in U.S. Recurrent Glioblastoma Trial